ArticleOncotarget2016
Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.
James M Paul et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
16 papers cite it
this papercites it
ArticleOncotarget2016
James M Paul et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.